Non-Invasive Malignancy Classifiers Using Blood-Biomarkers for Lung Nodule Evaluation
NIMBLE | Non-Invasive Malignancy Classifiers Using Blood-Biomarkers for Lung Nodule Evaluation
Herlev and Gentofte Hospital
1,800 participants
May 22, 2024
OBSERVATIONAL
Conditions
Summary
The goal of the NIMBLE study is to evaluate blood-based biomarkers for lung cancer risk prediction in patients referred with a lung nodule. Each blood biomarker will be evaluated for descriminating malignant from benign lung nodules alone and in combination with other blood biomarkers, patient characteristics and radiological features.
Eligibility
Inclusion Criteria2
- Patients with a newly detected IPN suspected of lung cancer referred to the infiltrate unit
- Having signed informed consent
Exclusion Criteria2
- Active cancer, excluding non-melanoma skin cancer
- Comorbidities that exclude the patient from clinical follow-up and final diagnosis
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Standard blood tests, Novel protein tumor markers specifically targeting lung cancer, Epigenetic smoking marker (AHRR methylation), Combined fragmentome, mutational and methylome analysis of cell-free tumor DNA
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07623473